Nexien BioPharma, Inc.
NXEN
Other OTC0.00
USD
- -
- -
CIK
0001625288
ISIN
US65343D1000
CUSIP
65343D100
Return %
Stock
S&P500
1Y
-99.33
26.53
3Y
-99.78
76.60
5Y
-99.90
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Richard S. Greenberg
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 4340 East Kentucky Avenue Glendale CO United States of America 80246
- IPO Date
- Nov 29, 2017
- CIK
- 0001625288
- Website
- nexienbiopharma.com
- Similar Companies
- Business
- Nexien BioPharma, Inc. operates as a pharmaceutical development company specializing in the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, drug delivery systems, and related technologies. The company's core products include proprietary cannabinoid pharmaceuticals and advanced drug delivery platforms such as precision parenteral formulations and innovative tablet technologies—PerfectDose™ for human applications and Triit™ for veterinary use—designed for accurate oral and sublingual dosing of cannabinoid active pharmaceutical ingredients (APIs) with or without adjunct APIs. Nexien BioPharma focuses its R&D efforts on treatments for specific medical conditions, including convulsive disorders and neuromuscular disorders, in accordance with U.S. Food and Drug Administration (FDA) regulatory pathways. The company operates through strategic alliances with academic research institutions, contract research organizations (CROs), and contract development and manufacturing organizations (CDMOs), maintaining compliance with U.S. Drug Enforcement Administration (DEA) licensing requirements. Founded in 1952 and headquartered in Glendale, Colorado, Nexien BioPharma recently expanded its capabilities through the acquisition of CRx Bio, a Princeton-based biotechnology company, enhancing its intellectual property portfolio and drug development expertise in cannabinoid therapeutics. Additionally, Nexien BioPharma has secured funding via private placements including a recent round with Quick Capital, LLC, reinforcing its capital structure to support continued R&D and commercialization activities. The company operates primarily within the United States pharmaceutical and biomedical sectors, targeting both human and veterinary medicine markets with its cannabinoid-based therapeutic innovations. This integration of proprietary drug formulations, delivery technologies, and strategic acquisitions underscores Nexien BioPharma's commitment to advancing cannabinoid pharmaceuticals for clinical use across multiple therapeutic indications.